The new platform funded by the NCI and the National Institutes of Health, demonstrates how angiogenic inhibitors affect simultaneously entire cells and several steps of the angiogenesis process.
Bend has provided Merck with the rights to have access to its proprietary spray-dried dispersion (SDD) technology, as per the agreement. Bend will also provide Merck with access
Proteoderm has used non-embryonic stem cells to develop a matrix of proteins (Matrix NC-138) used to harness the anti-aging potential in cosmeceutical products. Proteonomix president Michael Cohen said
The randomized trial was designed to assess whether the investigational alemtuzumab could achieve efficacy and safety improvements over the approved interferon beta-1a (Rebif). The trial enrolled patients who
The studies demonstrated once-monthly peginesatide, compared to epoetin alfa or epoetin beta dosed up to 13 times a month, maintained Hb levels in CKD patients on dialysis with
Iluvien is the company’s investigational sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide (FAc) to treat diabetic macular edema (DME) associated with diabetic retinopathy. FDA
During the study, Apixaban had failed to meet the primary efficacy outcome of superiority to Enoxaparin drug for the endpoint of VTE and VTE-related death. Brigham and Women’s
As per the agreement, ROP has received initial $100K licensing fee from BioStructures and will also receive an additional license fees as well as royalties on sales throughout
The new double-blind, placebo-controlled, randomized Phase II clinical trial is expected to recruit 64 relapsing-remitting or secondary-progressive female MS patients aged between 18 and 50. The primary endpoint
Ampion is a non-steroidal anti inflammatory drug indicated for treatment in the homeostasis of inflammation. During the course of the study, twenty patients were randomized to receive either
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.